Product Introduction
Bioactivity


英文名: Cevoglitazar

描述: Cevoglitazar (LBM-642) 是一种 PPARɑ 激动剂和 PPARγ激动剂。Cevoglitazar 能有效减少肥胖小鼠和猴的食物摄入量和体重。

体内活性: Cevoglitazar (0.5 mg/kg; 7 d) plasma levels of glucose and insulin were normalized.[1] Cevoglitazar (50 and 500 mg/kg; obese and insulin-resistant cynomolgus monkeys; 4 weeks) lowered food intake and body weight in a dose-dependent manner. In these animals, cevoglitazar also reduced fasting plasma insulin and, at the highest dose, reduced hemoglobin A1c levels by 0.4%.[1]Cevoglitazar (5 mg/kg) reduced BW gain and adiposity, independent of food intake. In the muscle, cevoglitazar improves the lipid profile via both PPARalpha- and PPARgamma-mediated mechanisms, and cevoglitazar reduced hepatic lipid concentration below baseline levels (p < 0.05). Metabolic profiling showed that in the liver, cevoglitazar functions largely through PPARalpha agonism resulting in increased beta-oxidation. Cevoglitazar only induced small changes to the lipid composition of visceral fat.[2]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 50 mg/mL (89.52 mM)


关键字: Cevoglitazar

相关产品: Gypenoside XLIX | Seratrodast | Gallocatechin gallate | MSDC-0602K | T0070907 | Daidzein | Arhalofenate | Tesaglitazar | G3335 Acetate | BAY-0069

相关库: Bioactive Compounds Library Max | Anti-Obesity Compound Library | Bioactive Compound Library